What if… we could unlock the full power of medicines?

Transforming Treatments Means Transforming Lives

We all rely on medicines. But they don’t always work as intended. Too often, they’re held back by fundamental limitations such as side effects or no targeting. We are here to change this. ProSilic® is our bio-courier engineered to maximise the therapeutic benefits of drug molecules and active ingredients.

Company

We are a commercial-stage drug development company. Our pharmaceutical pipeline is focussed on reformulating existing medicines to make them more effective. We also develop formulations for clients, our own subsidiaries and grant-funded R&D projects.

Pipeline

Team

Led by entrepreneur, inventor, and scientist, Dr Suzanne Saffie-Siebert, our management team has a wealth of executive experience in pharmaceutics, skincare and animal health.

Meet The Team

Technology

ProSilic® is our patented bio-courier technology. It’s a hybrid of porous silicon and liposomes and can be engineered to take even the most challenging molecules to their target, optimising efficacy and safety.

More

Why Invest?

New drug discovery is expensive, time consuming and risky.
We’re focussed on a faster, lower risk approach to drug development.

More

News

Croda Invests in SiSaf’s Novel Bio-Courier Technology

More

UK based biopharmaceutical company SiSaf closes $4.3 million interim funding round

More

SiSaf’s Chairwoman and Chief Executive Officer, Suzanne Saffie-Siebert featured on BBC Radio 4’s ‘In Business’

More

Next-gen silicon nanotechnology drug delivery company SiSaf raises $3.5 million in Series A Funding

More

Silicon Valley Investors Lead Funding Round in SiSaf

More

SiSaf Releases latest Clinical Data Showing a 95% Reduction in Acne

More